Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

FNArena Corporate Results Monitor – 09-02-2024

Feb 09 2024

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


Destocking Remains Amcor’s Hobgoblin

Feb 08 2024

Amcor suffered volume declines in the first half which are set to carry into the second, given customer destocking and weak end-consumer demand


FNArena Corporate Results Monitor – 08-02-2024

Feb 08 2024

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


Monthly Listed Investment Trust Report – Feb 2024

Feb 07 2024

Independent Investment Research updates developments in Australia’s listed investment trust and provides comparative data


FNArena Corporate Results Monitor – 07-02-2024

Feb 07 2024

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


January In Review: Large Caps Back In The Lead

Feb 06 2024

The ASX200 gained 1.2% in January on expectations for falling interest rates, with energy and financial stocks grabbing the lead


FNArena Corporate Results Monitor – 05-02-2024

Feb 05 2024

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


The Market In Numbers – 3 Feb 2024

Feb 03 2024

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements


Tough Times For IGO

Feb 01 2024

Asset write-downs, production guidance cuts, processing issues – it’s been a tough time for IGO amidst falling lithium and nickel price falls


ResMed Recovery Turns Into Hollywood Script

Jan 31 2024

More troubles for key competitor Philips/Respironics suggests there could be more momentum shifting in ResMed’s favour



Analyse The Market From A Different Angle